At UAS we continually invest in gold-standard clinical trials for both single strains and finished formulations. We take pride in advancing the industry with scientific data and clinical research.
Our Chief Scientific Officer, Dr. Gregory Leyer has dedicated his professional career to probiotic advancement. He has authorship in over 20 probiotic-related publications and is an active member of the International Probiotic Association (IPA) and International Scientific Association for Probiotics and Prebiotics (ISAPP).
Dr. Greg leads our in-house research teams as they apply their knowledge of ingredient combinations and clinical documentation to formulate probiotics that support desired structure-function claims. The team does not hesitate when it comes to investing in strains with promise. We will do what’s necessary to complete research and confirm the strain’s related health benefits.
Our team has completed extensive research on two clinically-validated trademarked superstrains:
Lactobacillus acidophilus DDS®-1
Our original trademarked superstrain, Lactobacillus acidophilus DDS®-1, is one of the longest studied probiotic strains with over 35 years of clinical research. Learn More…
Lactobacillus gasseri BNR17™
The most recent addition to our UAS line-up is superstrain Lactobacillus gasseri BNR17™, an extensively studied probiotic strain shown to provide both gastrointestinal and weight management support. Learn More…